• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Case: Secondary polycythemia due to pazopanib in patients with metastatic renal cell carcinoma.

作者信息

Bukhari Nedal, Winquist Eric

机构信息

Division of Medical Oncology, Department of Oncology, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada.

出版信息

Can Urol Assoc J. 2017 Nov;11(11):E449-E450. doi: 10.5489/cuaj.4519.

DOI:10.5489/cuaj.4519
PMID:29072563
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5698026/
Abstract
摘要

相似文献

1
Case: Secondary polycythemia due to pazopanib in patients with metastatic renal cell carcinoma.病例：转移性肾细胞癌患者因帕唑帕尼导致的继发性红细胞增多症。
Can Urol Assoc J. 2017 Nov;11(11):E449-E450. doi: 10.5489/cuaj.4519.
2
Symptomatic Secondary Polycythemia Induced by Anti-VEGF Therapy for the Treatment of Metastatic Renal Cell Carcinoma: A Case Series and Review.抗血管内皮生长因子（VEGF）治疗转移性肾细胞癌所致症状性继发性红细胞增多症：病例系列及文献综述
Clin Genitourin Cancer. 2015 Dec;13(6):e391-5. doi: 10.1016/j.clgc.2015.07.003. Epub 2015 Jul 26.
3
Guillain-Barré syndrome in a patient with renal cell carcinoma following the first course of pazopanib therapy.一名肾细胞癌患者在接受首个疗程的帕唑帕尼治疗后发生吉兰-巴雷综合征。
J Infect Chemother. 2017 Nov;23(11):798-799. doi: 10.1016/j.jiac.2017.04.014. Epub 2017 May 13.
4
Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study.国际转移性肾细胞癌数据库联盟（IMDC）转移性肾癌一线帕唑帕尼预后模型的验证：西班牙肿瘤泌尿学组（SOGUG）SPAZO研究
Ann Oncol. 2016 Apr;27(4):706-11. doi: 10.1093/annonc/mdv601. Epub 2015 Dec 9.
5
Cost-effectiveness of Pazopanib Versus Sunitinib as First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma from an Italian National Health Service Perspective.从意大利国家医疗服务体系的角度看，帕唑帕尼与舒尼替尼作为局部晚期或转移性肾细胞癌一线治疗的成本效益
Clin Ther. 2017 Mar;39(3):567-580.e2. doi: 10.1016/j.clinthera.2017.01.017. Epub 2017 Feb 9.
6
Effect of Concomitant pH-Elevating Medications with Pazopanib on Progression-Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma.帕唑帕尼联合 pH 升高药物对转移性肾细胞癌患者无进展生存期和总生存期的影响。
Oncologist. 2018 Jun;23(6):686-692. doi: 10.1634/theoncologist.2017-0578. Epub 2018 Feb 27.
7
Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib.使用帕唑帕尼对转移性肾细胞癌进行长期控制。
Case Rep Oncol. 2019 Jul 16;12(2):543-547. doi: 10.1159/000501716. eCollection 2019 May-Aug.
8
Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report.成功重新给予帕唑帕尼治疗一名转移性肾细胞癌且曾发生帕唑帕尼诱导的肾病综合征的患者：病例报告。
BMC Nephrol. 2019 Jan 3;20(1):1. doi: 10.1186/s12882-018-1181-1.
9
Pazopanib-related tumor lysis syndrome in metastatic clear cell renal cell carcinoma: a case report.帕唑帕尼相关性肿瘤溶解综合征伴转移性透明细胞肾细胞癌：一例报告。
Invest New Drugs. 2018 Jun;36(3):513-516. doi: 10.1007/s10637-018-0576-y. Epub 2018 Feb 20.
10
Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study).帕唑帕尼治疗晚期肾细胞癌患者的前瞻性观察研究（PRINCIPAL 研究）。
Oncologist. 2019 Apr;24(4):491-497. doi: 10.1634/theoncologist.2018-0787. Epub 2019 Mar 13.

引用本文的文献

1
The role of mean corpuscular volume and red cell distribution width in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: the MARECAP retrospective study.平均红细胞体积和红细胞分布宽度在接受酪氨酸激酶抑制剂治疗的转移性肾细胞癌患者中的作用：MARECAP回顾性研究
Ther Adv Urol. 2023 Jul 22;15:17562872231187216. doi: 10.1177/17562872231187216. eCollection 2023 Jan-Dec.
2
Progressive erythrocytosis under lenvatinib treatment in patients with advanced hepatocellular carcinoma.在晚期肝细胞癌患者中，仑伐替尼治疗下的进行性红细胞增多症。
Cancer Chemother Pharmacol. 2023 Apr;91(4):337-344. doi: 10.1007/s00280-023-04519-6. Epub 2023 Mar 24.
3
Primary Intracranial Solitary Fibrous Tumor With Metachronous Pulmonary and Bone Metastasis: A Case Report.原发性颅内孤立性纤维瘤伴异时性肺和骨转移：一例报告
Cureus. 2022 Dec 16;14(12):e32607. doi: 10.7759/cureus.32607. eCollection 2022 Dec.
4
Metastatic Type II Papillary Renal Cell Carcinoma With Recurrent Complete Responses to Sunitinib: A Case Report With a Literature Review.转移性II型乳头状肾细胞癌对舒尼替尼反复出现完全缓解：一例报告并文献复习
Cureus. 2022 May 31;14(5):e25541. doi: 10.7759/cureus.25541. eCollection 2022 May.
5
Acute Lower Extremity Arterial Thrombosis Associated with Osimertinib-Induced Erythrocytosis.奥希替尼引起的红细胞增多症相关急性下肢动脉血栓形成。
Am J Case Rep. 2021 Sep 7;22:e932252. doi: 10.12659/AJCR.932252.
6
Sunitinib: An Unusual Cause of Pneumothorax in a Patient With Metastatic Chromophobe Renal Cell Carcinoma.舒尼替尼：转移性嫌色细胞肾细胞癌患者气胸的罕见病因。
Cureus. 2020 Aug 6;12(8):e9586. doi: 10.7759/cureus.9586.

本文引用的文献

1
Prognostic Significance of Increases in Hemoglobin in Renal Cell Carcinoma Patients During Treatment With VEGF-directed Therapy.肾细胞癌患者在接受VEGF靶向治疗期间血红蛋白升高的预后意义
Clin Genitourin Cancer. 2017 Jun;15(3):396-402. doi: 10.1016/j.clgc.2016.12.009. Epub 2016 Dec 13.
2
Paraneoplastic syndromes are associated with adverse prognosis among patients with renal cell carcinoma undergoing nephrectomy.副肿瘤综合征与接受肾切除术的肾细胞癌患者的不良预后相关。
World J Urol. 2016 Oct;34(10):1465-72. doi: 10.1007/s00345-016-1793-7. Epub 2016 Feb 25.
3
Symptomatic Secondary Polycythemia Induced by Anti-VEGF Therapy for the Treatment of Metastatic Renal Cell Carcinoma: A Case Series and Review.抗血管内皮生长因子（VEGF）治疗转移性肾细胞癌所致症状性继发性红细胞增多症：病例系列及文献综述
Clin Genitourin Cancer. 2015 Dec;13(6):e391-5. doi: 10.1016/j.clgc.2015.07.003. Epub 2015 Jul 26.
4
Successful treatment of erythropoietin-producing advanced renal cell carcinoma after targeted therapy using sunitinib: Case report and review of the literature.舒尼替尼靶向治疗后成功治疗促红细胞生成素产生性晚期肾细胞癌：病例报告及文献复习
Mol Clin Oncol. 2013 Jan;1(1):112-116. doi: 10.3892/mco.2012.5. Epub 2012 Aug 3.
5
Pazopanib versus sunitinib in metastatic renal-cell carcinoma.帕唑帕尼对比舒尼替尼用于转移性肾细胞癌。
N Engl J Med. 2013 Aug 22;369(8):722-31. doi: 10.1056/NEJMoa1303989.
6
Leukemia kidney infiltration can cause secondary polycythemia by activating hypoxia-inducible factor (HIF) pathway.白血病肾脏浸润可通过激活低氧诱导因子（HIF）通路引起继发性红细胞增多症。
Eur J Pediatr. 2013 Jun;172(6):829-32. doi: 10.1007/s00431-013-2030-7. Epub 2013 May 16.
7
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.接受血管内皮生长因子靶向药物治疗的转移性肾细胞癌患者总生存的预后因素：一项大型多中心研究的结果
J Clin Oncol. 2009 Dec 1;27(34):5794-9. doi: 10.1200/JCO.2008.21.4809. Epub 2009 Oct 13.
8
Role of vascular endothelial growth factor in kidney disease.血管内皮生长因子在肾脏疾病中的作用。
Curr Vasc Pharmacol. 2010 Jan;8(1):122-8. doi: 10.2174/157016110790226606.
9
Axitinib induces paradoxical erythropoietin synthesis in metastatic renal cell carcinoma.阿昔替尼可诱导转移性肾细胞癌中出现反常的促红细胞生成素合成。
J Clin Oncol. 2009 Jan 20;27(3):472-3; author reply 473-4. doi: 10.1200/JCO.2008.20.1087. Epub 2008 Dec 15.
10
Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.酪氨酸激酶抑制剂舒尼替尼和索拉非尼引起的继发性红细胞增多症。
J Clin Oncol. 2008 Aug 20;26(24):4047-8. doi: 10.1200/JCO.2008.18.3525.